The US Food and Drug Administration (FDA) has approved BD Rx's second injectable antiemetic, BD Simplist Metoclopramide Injection, USP.
BD Simplist prefilled injectables are designed to enhance patient care and safety by minimizing the number of steps in the traditional vial and syringe injection sequence, cutting the potential risk of medication error, according to the company.
BD Rx president Mark Sebree said after a successful launch of BD Simplist prefilled injectables; the company is excited to be coming out with a second drug that is commonly used by clinicians.
"This is just the beginning of our new line of prefilled injectable products," Sebree added.
On 27 March 2013, BD Rx launched its first drug, BD Simplist Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine.
BD Rx is a wholly-owned subsidiary of medical technology company Becton, Dickinson and Company.
